NEUROBiOGEN

본문 바로가기 주메뉴 바로가기

Comunications

NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.

News

News
Notice

News

Here are news on NEUROBIOGEN (currently in Korean only).

NO	SUBJECT	DATE	VIEW
29	Neurobiogen 'New Drug to Treat Brain Diseases' Approved for Phase 1 Clinical Treatment in Korea.	2022. 03. 02	657
28	Neurobiogen, MAO-B Target Dementia Clinic Phase 1 Authorization.	2022. 03. 02	677
27	Neurobiogen Proposes Possible Treatment of New Drug Substance 'KDS2010' Parkinson's Disease.	2021. 10. 14	737
26	Neurobiogen, New Drug Candidate Material KDS2010 Proposes Possible Treatment of Parkinson's Disease.	2021. 10. 12	732
25	Neurobiogen, suggesting the possibility of treating Parkinson's disease.	2021. 10. 12	1181
24	Neurobiogen Proposes Possible Treatment of New Drug Substance 'KDS2010' Parkinson's Disease.	2021. 10. 12	753
23	Kim Sang-wook, CEO of Neurobiogen, said, "Our Alzheimer's treatment has a different target in itself."	2021. 10. 05	814
22	Neurobiogen, 'New Target' for Alzheimer's Dementia Development...Apply for Phase 1 clinical IND this year.	2021. 10. 05	691
21	Neurobiogen "Dental effects of dementia drugs...Investment attraction drive."	2021. 09. 15	683
20	Change the paradigm of treating Alzheimer's...Clinical Applications within the Year.	2021. 09. 09	685

6 7 8 9 10